MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively furthe ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s MedTech “looks well-positioned on several fronts.” The firm also thinks that ma ...

Core Insights - Planisware has opened a new office and two data centers in Australia, marking a significant step in its international development strategy and strengthening its presence in the Asia-Pacific region [2][4][6] Company Expansion - The Australian market is identified as a dynamic opportunity, particularly in the industrial, healthcare, energy, and utilities sectors, with existing flagship customers including Coles, Cochlear, Breville, Seqwater, and Sunwater [3][4] - Planisware has experienced an average annual growth of 33% from 2020 to 2024, driven by increasing demand for integrated project management and digital transformation solutions [4] Data Centers and Security - The investment in two new data centers aims to provide optimal performance and total data sovereignty, adhering to high security standards [5] Leadership and Strategy - Cédric Bastien has been appointed to lead the new office in Australia, bringing over 15 years of experience in managing international projects and a strong commitment to customer service [6][8] - The expansion in Australia is part of Planisware's ambition to become the preferred partner for companies focused on project performance [6]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation and certain executives, alleging misleading statements and failure to disclose adverse facts about the company's business and operations during the class period from July 25, 2024, to October 22, 2025 [1] Company Overview - Integer Holdings Corporation, based in Plano, Texas, is one of the largest medical device contract development and manufacturing organizations globally, focusing on cardiac rhythm management and cardiovascular medical devices [2] - Approximately 60% of Integer's total revenue is generated from its cardiovascular product line, which includes electrophysiology devices that diagnose and map the heart's electrical activity [2] Industry Context - Prior to the class period, the electrophysiology device market experienced a technological revolution with the development of pulse field ablation procedures, which treat atrial fibrillation [3] - The integration of electrophysiology devices and pulse field ablation platforms became a significant growth driver for Integer's cardiovascular segment [3] Allegations in the Class Action - The lawsuit claims that during the class period, Integer's executives made materially false and misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [4] - Specific allegations include: 1. Integer overstated its competitive position in the EP manufacturing market 2. The company experienced a deterioration in sales for two of its EP devices, contrary to claims of strong customer demand 3. Integer mischaracterized its EP devices as a long-term growth driver for its cardiovascular segment [4] Disclosure of Financial Performance - On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, which was below analysts' expectations [5] - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, with expectations of declining sales for three new products, including two electrophysiology products [5] - Following this disclosure, Integer's stock price fell by $35.22, or over 32%, from $109.11 to $73.89 per share [5]

Summary of Conference Call on China Healthcare Industry and Companies Industry Overview - **Sector**: China Healthcare, specifically focusing on hospital equipment bidding - **Key Data**: November 2025 public hospital medical equipment bidding value increased by **15% YoY**, surpassing previous expectations of flat-to-low single-digit growth [1] Core Insights - **Bidding Activity**: - The increase in bidding value was unexpected, as leading indicators suggested weaker dynamics for 2025 compared to 2024 [1] - United Imaging indicated that while trade-in program execution is faster than last year, some procurement may be deferred to 2026, suggesting a recovery in non-trade-in demand [1] - **Future Outlook**: - A cautious stance is maintained for bidding activity into December 2025 and the first half of 2026 due to tougher base effects and uneven trade-in execution across regions [2] - The base-case assumption for bidding value has been revised from a flat-to-single-digit decline to flat-to-modest YoY growth for December 2025 and 1H26 [2] Company-Specific Insights United Imaging - **Performance**: - Domestic revenue grew **73% YoY** in 3Q25, driven by previous hospital bidding revenue recognition; overseas revenue increased by **81% YoY** [14] - Service revenue grew **22% YoY**, indicating resilience to economic cycles [14] - November growth was **30% YoY**, significantly higher than the industry average of **15%** [14] - **Valuation**: - Currently trading near its median P/E multiple since listing, with significant long-term net profit growth potential anticipated [14] Mindray - **Performance**: - Core businesses showed mixed results: PMLS grew **2.6%**, MI grew **1%**, while IVD declined **2.8%** in 3Q25 [16] - Domestic PMLS revenue decline narrowed to **-25%** from **-57%** in 1H25, with overseas sales up **14% YoY** [16] - Management expects destocking to complete by 4Q25, with revenue recovery anticipated in 2026 [16] - **Growth Drivers**: - Long-term double-digit growth supported by recurring business in China and market share gains in emerging markets [16] - High-potential products expected to drive significant revenue growth in China from 2024 to 2035 [16] Risks and Challenges - **Mindray**: - Risks include potential impacts from VBP on product pricing, challenges in penetrating top-tier hospitals, and difficulties in entering North American and European markets [77] - **United Imaging**: - Risks include chip supply chain issues, raw material risks, macroeconomic downturns in China, and potential VBP risks [78] Investment Ratings - **Mindray**: Rated as "Buy" with a 12-month target price of **Rmb285**, indicating an upside of **43.4%** [79] - **United Imaging**: Rated as "Buy" with a 12-month target price of **Rmb174**, indicating an upside of **34.9%** [82] Conclusion - The China healthcare equipment sector is showing signs of recovery with better-than-expected bidding activity, particularly for United Imaging. Mindray is facing challenges but has potential growth drivers in emerging markets and high-potential products. Both companies are rated as "Buy" with significant upside potential.

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is focused on claims that Tandem Diabetes Care may have misled investors regarding its business practices [1]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses, allowing affected shareholders to join without upfront costs [2]. Group 2: Incident Overview - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its next-generation device, the Inspire V, leading to significant financial losses for investors [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its operational readiness for the Inspire V launch, stating it was ready for a full commercial rollout, while concealing critical operational failures [3][4]. - Key undisclosed operational issues included delays in Medicare claims processing software updates, which only took effect on July 1, 2025, causing revenue bottlenecks [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, necessitating an inventory "burn down" [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, further hindering the launch [4]. Group 2: Financial Consequences - The alleged operational failures led Inspire Medical to cut its 2025 earnings per share (EPS) guidance by over 80%, resulting in a significant stock price drop of $42.04 per share, equating to a 32.4% decline in value [4][5]. - The lawsuit highlights that the stock collapse was attributed to management prioritizing a narrative of seamless transition over the actual operational challenges faced [5]. Group 3: Legal and Investigative Actions - Hagens Berman, the law firm leading the investigation, is encouraging investors who suffered losses during the class period from August 6, 2024, to August 4, 2025, to contact them before the January 5, 2026, lead plaintiff deadline [2][3]. - The firm is particularly focused on the concealment of the Medicare claims software failure and the inventory issues related to the Inspire IV device [5].

Core Insights - The FDA has cleared the da Vinci Single Port (SP) surgical system for inguinal hernia repair, cholecystectomy, and appendectomy, expanding its capabilities in minimally invasive surgery [1][2]. Group 1: Product Expansion - The new clearances build on existing approvals for urology, colorectal, thoracic, and transoral procedures, enhancing the versatility of the da Vinci SP system [2]. - The da Vinci SP system allows surgeons to perform procedures through a single incision or natural orifice, providing enhanced visualization and precision [3]. Group 2: Innovation and Commitment - The company emphasizes its commitment to innovation, aiming to improve patient care through less invasive approaches that reduce recovery time and overall costs [4]. - There is a growing body of evidence, including over 500 peer-reviewed publications, supporting the safety and efficacy of the da Vinci SP system [4]. Group 3: Company Overview - Intuitive, headquartered in Sunnyvale, California, is a leader in minimally invasive care and robotic surgery, with technologies including the da Vinci surgical system and the Ion endoluminal system [5]. - The da Vinci surgical systems are designed to assist surgeons with high-definition 3D vision and specialized instrumentation for precise dissection and reconstruction [6].